Avastin Efficacy
Links shared publicly online about this topic
Primary Intravitreal Avastin® (bevacizumab) Shows Some Efficacy in Diffuse DME at 24 Months
eyedocnews.com — “Researchers report that intravitreal bevacizumab provides some improvement in BCVA and CMT in patients with diffuse DME.” View full resource at eyedocnews.com
Most Recently Shared on July 2, 2009 at 4:51 pm By:
Dr. Ari Weitzner Doctor, Ophthalmologist, and Physician
Discuss: Primary Intravitreal Avastin® (bevacizumab) for Diffuse DME: The Pan-American Collaborative Ret.. http://tinyurl.com/lu8h9p
Medical News, FAQ, and Pearls: Avastin (bevacizumab) and Lucentis (ranibizumab) demonstrate similar efficacy for treatment of age-related macular degeneration
medrounds.org — “Medical News, FAQ, and Pearls: Avastin (bevacizumab) and Lucentis (ranibizumab) demonstrate similar efficacy for treatment of age-related macular degeneration” View full resource at medrounds.org
Most Recently Shared on November 10, 2009 at 5:45 am By:
Andrew Doan, MD, PhD PhD, Doctor, Ophthalmologist, and Physician
Avastin and Lucentis demonstrate similar efficacy for treatment of age-related macular degeneration: http://bit.ly/1Bl4u1 via @addthis
FDA questions breast cancer drug Avastin
examiner.com — “The drug Avastin gained approval to treat breast cancer from the FDA in 2008. Now, the FDA is questioning the drug's efficacy. The initial approval was an accelerated approval, granted because of initial, positive research. …” View full resource at examiner.com
Most Recently Shared on July 23, 2010 at 10:00 pm By:
FDA questions #breastcancer drug Avastin http://exm.nr/bqUiD3
Roche likes odds of Avastin approval in ovarian cancer - FierceBiotech
fiercebiotech.com — “Roche's Avastin has been in a bit of a slump after recent questions about its safety and efficacy in treating certain tumors, but the Swiss drug giant could get a boost with potential new approvals Read more...” View full resource at fiercebiotech.com
Most Recently Shared on May 27, 2011 at 1:58 pm By:
Roche likes odds of Avastin approval in ovarian cancer. http://bit.ly/kfIODm
Cancer drug is no different in effectiveness as gold standard treatment for macular degeneration
physorg.com — “Investigators from Boston University School of Medicine (BUSM) and the VA Boston Healthcare System have shown, at 6 months in a small group of patients, that there is no difference in efficacy between Bevacizumab (Avastin) and Ranibizumab (Lucentis) for the treatment of age-related macular degeneration ...” View full resource at physorg.com
Most Recently Shared on October 9, 2009 at 3:08 pm By:
Cancer drug is no different in effectiveness as gold standard treatment for macular degeneration http://bit.ly/Tpb42
Cancer Drug Is No Different In Effectiveness As Gold Standard Treatment For Macular Degeneration
medicalnewstoday.com — “Investigators from Boston University School of Medicine (BUSM) and the VA Boston Healthcare System have shown, at 6 months in a small group of patients, that there is no difference in efficacy bet” View full resource at medicalnewstoday.com
Most Recently Shared on October 12, 2009 at 1:01 pm By:
MNT Clinical Trials Health News
Cancer Drug Is No Different In Effectiveness As Gold Standard Treatment For Macular Degeneration: Investigators.. http://bit.ly/mT68l
Drugs for macular degeneration - QualityPoint Technologies
qualitypointtech.net — “(Boston) Scientists from Boston University School of Medicine (BUSM) and the VA Boston Healthcare System have conducted a study that failed to show a difference in efficacy between Bevacizumab (Avastin) and Ranibizumab (Lucentis) for the therapy of age-related macular degeneration (AMD). The study, which appears currently on-line in Eye, is thought to bethe first study to describe one-year outcomes of a prospective, double-masked, randomized clinical trial directly comparing bevacizumab to ranib” View full resource at qualitypointtech.net
Most Recently Shared on October 1, 2010 at 12:36 pm By:
Drugs for macular degeneration: (Boston) Scientists from Boston University School of Medicine (BUSM) and the VA Bo... http://bit.ly/d5SiAe
The Top 3 resources shared on this topic. More resources.
Key stats and trends about this topic
Featuring the top 3 experts for this topic
-
Dr. Ari Weitzner
Brooklyn, NY Ophthalmologist; Editor of EyeDocNews; Founder of Share Medical Space
-
Andrew Doan, MD, PhD
Board certified ophthalmologist and eye pathologist with expertise in internet marketing, search engine optimization, and publishing.
-
SeniorHomes.com
A free resource for people looking for senior care or housing.
Advertisement
